At week 26 , HbA1c decreased from baseline by -0.82 SE 0.06 % ( 9.0 mmol/mol ) with albiglutide and -0.66 0.06 % ( 7.2 mmol/mol ) with lispro ; treatment difference , -0.16 % ( 95 % CI -0.32 to 0.00 ; 1.8 mmol/mol ; P < 0.0001 ) , meeting the noninferiority end point ( margin , 0.4 % ) .